John Houston
Net worth: 9 M $ as of 31/05/2026
Net worth: 9 M $ as of 31/05/2026
John G. Houston holds the position of President, Chief Executive Officer & Director at Arvinas, Inc. and President, Chief Executive Officer & Director at Arvinas Operations, Inc. (a subsidiary of Arvinas, Inc.). He is also on the board of NextCure, Inc., Cybrexa, Inc. and Oerth Bio LLC. John G. Houston previously occupied the position of Senior Vice President-Specialty Discovery at Bristol Myers Squibb Co. and Head-Lead Discovery Unit at GlaxoSmithKline Research & Development Ltd. He received a doctorate from the University of Glasgow and a doctorate from Heriot-Watt University.
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
ARVINAS, INC. 1.54% | 31/03/2026 | 992,689 ( 1.54% ) | 9 M $ | 31/05/2026 |
NEXTCURE, INC. -.--% | 22/04/2026 | 0 ( -.--% ) | - $ | 31/05/2026 |
| Companies | Position | Start |
|---|---|---|
| ARVINAS, INC. | Director/Board Member | 12/02/2026 |
| NEXTCURE, INC. | Director/Board Member | 10/09/2020 |
Arvinas Operations, Inc.
Arvinas Operations, Inc. BiotechnologyHealth Technology Develops protein degradation therapeutics for cancer and other diseases | Chief Executive Officer | 21/09/2017 |
Cybrexa, Inc.
Cybrexa, Inc. BiotechnologyHealth Technology Develops molecule DNA repair inhibitors that directly target the tumor microenvironment | Director/Board Member | 03/09/2019 |
Oerth Bio LLC
Oerth Bio LLC BiotechnologyHealth Technology Develops biotechnology products | Director/Board Member | 01/06/2019 |
Connecticut United for Research Excellence, Inc.
Connecticut United for Research Excellence, Inc. Miscellaneous Commercial ServicesCommercial Services Provides support services for biomedical research and biotechnology to advance and support research and technology | Director/Board Member | 01/12/2015 |
Bioct Innovation Commons | Director/Board Member | 01/12/2015 |
| Companies | Position | End |
|---|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | 01/08/2016 |
GlaxoSmithKline Research & Development Ltd.
GlaxoSmithKline Research & Development Ltd. Miscellaneous Commercial ServicesCommercial Services Functions as a commercial physical research company | Corporate Officer/Principal | - |
Active
Inactive
Listed companies
Private companies
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
| Private companies | 11 |
|---|---|
Bristol Myers Squibb Co.
Bristol Myers Squibb Co. Pharmaceuticals: MajorHealth Technology Manufactures and markets biopharmaceuticals products | Health Technology |
Arvinas Operations, Inc.
Arvinas Operations, Inc. BiotechnologyHealth Technology Develops protein degradation therapeutics for cancer and other diseases | Health Technology |
University of Glasgow
University of Glasgow Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Heriot-Watt University
Heriot-Watt University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Connecticut United for Research Excellence, Inc.
Connecticut United for Research Excellence, Inc. Miscellaneous Commercial ServicesCommercial Services Provides support services for biomedical research and biotechnology to advance and support research and technology | Commercial Services |
GlaxoSmithKline Research & Development Ltd.
GlaxoSmithKline Research & Development Ltd. Miscellaneous Commercial ServicesCommercial Services Functions as a commercial physical research company | Commercial Services |
Arvinas, Inc.
Arvinas, Inc. BiotechnologyHealth Technology Engages in discovery, development and commercialization of therapies to degrade disease-causing proteins | Health Technology |
NextCure, Inc.
NextCure, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company which discovers and develops novel immuno medicines to treat cancer & immune related diseases | Health Technology |
Cybrexa, Inc.
Cybrexa, Inc. BiotechnologyHealth Technology Develops molecule DNA repair inhibitors that directly target the tumor microenvironment | Health Technology |
Oerth Bio LLC
Oerth Bio LLC BiotechnologyHealth Technology Develops biotechnology products | Health Technology |
Bioct Innovation Commons | Finance |
Select your edition
All financial news and data tailored to specific country editions